share_log

Tilray Brands | 4: Statement of changes in beneficial ownership of securities-Officer Gendel Mitchell

Tilray Brands | 4: Statement of changes in beneficial ownership of securities-Officer Gendel Mitchell

Tilray Brands | 4：持股变动声明-高管 Gendel Mitchell
美股SEC公告 ·  2024/08/02 16:11

Moomoo AI 已提取核心信息

On July 31, 2024, Mitchell Gendel, the Global General Counsel of Tilray Brands, completed a stock transaction involving the company's common stock. Gendel acquired 93,926 shares through the exercise of derivative securities at a price of $2.03 per share. On the same day, he disposed of 47,950 shares at the same price, which was related to the payment of exercise price or tax liability by delivering or withholding securities. After these transactions, Gendel's direct holdings in Tilray Brands amounted to 420,268 shares. The total market value of the disposed shares was approximately $97,338.50.
On July 31, 2024, Mitchell Gendel, the Global General Counsel of Tilray Brands, completed a stock transaction involving the company's common stock. Gendel acquired 93,926 shares through the exercise of derivative securities at a price of $2.03 per share. On the same day, he disposed of 47,950 shares at the same price, which was related to the payment of exercise price or tax liability by delivering or withholding securities. After these transactions, Gendel's direct holdings in Tilray Brands amounted to 420,268 shares. The total market value of the disposed shares was approximately $97,338.50.
2024年7月31日，Tilray品牌的全球总法律顾问Mitchell Gendel以2.03美元的价格通过衍生证券行使权利，获得93,926股公司普通股的交易。当天，他以同样的价格出售47,950股股票，这与通过交付或扣减证券支付行权价格或税务责任有关。在这些交易后，Gendel在Tilray品牌的直接持股达到了420,268股。出售股份的总市值约为97,338.50美元。
2024年7月31日，Tilray品牌的全球总法律顾问Mitchell Gendel以2.03美元的价格通过衍生证券行使权利，获得93,926股公司普通股的交易。当天，他以同样的价格出售47,950股股票，这与通过交付或扣减证券支付行权价格或税务责任有关。在这些交易后，Gendel在Tilray品牌的直接持股达到了420,268股。出售股份的总市值约为97,338.50美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Citius Oncology
    CTOR
    -- 0.930
    脑再生科技
    RGC
    -- 31.880
    正业生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood医药
    IRWD
    -- 1.470
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点